BioNTech is trading at $88.13 (-4.37%) in after-hours trading following an isolated selloff with no clear company-specific catalyst.
- The decline follows a regular session close of $92.16, occurring despite a lack of new earnings releases, corporate announcements, or late-breaking news.
- The price action appears independent of the broader market, as the NASDAQ was trading slightly higher during the same period.
- Relevant sector news was limited to patent-lawsuit developments involving Moderna and CureVac, with no direct impact reported for BioNTech.